Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

Trial Profile

Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Irinotecan (Primary) ; Cyclophosphamide
  • Indications Ewing's sarcoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 05 Apr 2017 Preliminary pharmacokinetic and safety results (n=16) presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 27 Mar 2017 Data from this trial will be presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, according to a Merrimack Pharmaceuticals media release.
    • 02 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top